Total Funding
42
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
51081
Astria Therapeutics develops therapies for allergic and immunologic diseases.
Acquired by 
BioCryst Pharmaceuticals
- Andrea Matthews: Chief Business OfficerPast Role: Astria Therapeutics, Senior Vice President Corporate Affairs
John Ruesch: Senior Vice President, Pharmaceutical Sciences and Technical OperationsPast Role: Biogen, Vice President
About the Company
Astria Therapeutics is a biopharmaceutical company devoted to developing life-changing therapies for allergic and immunologic diseases. The company is advancing a pipeline of therapeutic candidates, including Navenibart for Hereditary Angioedema and STAR-0310 for Atopic Dermatitis. Astria Therapeutics conducts clinical trials and research, guided
by the patient community, to create new treatments.
Women Founded
Women Led
